Glaxo Smith Kline

GSK’S Introduction

GlaxoSmithKline often abbreviated to GSK, is a global

pharmaceutical, biologics, vaccines and consumer

healthcare company headquartered in London, United

Kingdom.
GSK’S Introduction

• It is world’s third largest pharmaceutical company

measured by revenues ( after Johnson and Johnson and
Pfizer.

• It has a portfolio of products for major disease areas

including asthma, cancer, virus control, infections, mental
health, diabetes and digestive conditions.
History

• GlaxoSmithKline plc is a public limited company incorporated

on 6th December 1999 under English law. Its shares are listed
on the London Stock Exchange and the New York Stock
Exchange.

• On 27th December 2000 the company acquired Glaxo

Wellcome plc and SmithKline Beecham plc, both English public
limited companies, by way of a scheme of arrangement for the
merger of the two companies.
History

• GSK and its subsidiary and associated undertakings

constitute a major global healthcare group engaged in the
creation, discovery, development, manufacture and
marketing of pharmaceutical and consumer health-related
products.

• GSK has its corporate head office in London and has its
US headquarters in Research Triangle Park, North
Carolina, with operations in some 120 countries, and
products sold in over
150 countries.
Chairman:
Sir Christopher Gent

Chief Executive Officer:

Andrew Witty
GSK’s Mission
GSK MISSION

GROW

MISSION

DELIVER
SIMPLYFY
GSK’S Mission

 Grow a diversified global business – We are

diversifying our business to create a more balanced
product portfolio and move away from a reliance on
traditional ‘white pill/western markets’. We are investing in
key growth areas such as Emerging Markets, Japan,
Vaccines and our Consumer Healthcare business.

.
GSK’S Mission

 Deliver more products of value – We aim to sustain an

industry-leading pipeline of products, ensuring that they
demonstrate value for healthcare providers. Our R&D
strategy is built around focusing on the best science,
diversifying through externalisation of research, and
improving the returns on investment.
GSK’S Mission

 Simplify the operating model – GSK is a large and

complex organisation. We are transforming our operating
model to reduce complexities, improve efficiency and
reduce costs
Products

1. Prescription medicines

2. Vaccines

3. Consumer Healthcare
PRESCRIPTION MEDICINES
ALLI-WEIGHT LOSS DRUG
AVANDIA-DIABETIS CONTROL
ROTAVIRUS VACCINE ROTARIX
VACCINE FOR MEASLES
CONSUMER HEALTHCARE
PRODUCTS
CONSUMER HEALTHCARE
PRODUCTS
Two other companies

• Stiefel, a GSK company—

A Global Leader in Dermatology

• ViiV Healthcare —
a global specialist HIV company
established by GlaxoSmithKline and Pfizer to deliver
advances in treatment and care for people
STIEFEL-A GSK COMPANY
VIIV- HEALTHCARE COMPANY
Turnover ( in billion pounds)
2009 28.4

2008 24.4

2007 22.7

2006 23.2

2005 21.7
World market by geographic
region
value(billion pounds) % of total
• USA 187 40
• Europe 131 28
• France 25 5
• Germany 24 5
• Italy 16 3
• UK 12 3
• Rest of World 150 32
• Emerging markets 66 14
• Asia Pacific 20 4
• Japan 50 11
• Canada 11 2
Regional analysis

(2009) (2008) cer% pnd%

• USA 9,180 8,894 (13) 3

• Europe 7,681 6,483 9 18

• Emerging Markets 2,973 2,290 20 30

• Asia Pacific/Japan 2,700 1,918 16 41

• Other trading‡ 1,180 796 31 48

23,714 20,381 2 16
• CER% represents growth at constant exchange rates.

• Pound % growth at actual exchange rates.

Consumer Healthcare
turnover(million pounds)

(2009) (2008) cer% pound %

Over the counter 2,319 1935 8 20
Medicines

Oral healthcare 1484 1240 7 20

Nutritional healthcare 851 796 3 7

Sales Trend
Five countries chosen

 USA

 JAPAN

 GERMANY

 SWITZERLAND

 UK
COMPETITORS IN USA

NAME OF THE COMPANY • TOTAL REVENUE(IN USD

BILLIONS )
1. Johnson & Johnson
• 61.90
2. Abbott Laboratories
• 30.76
3. Merck & Co.
• 27.43
4. Eli lilly

5. Bristol-Myers Squibb • 21.84

• 18.81
JOHNSON &JOHNSON
ABBOT LABORATARIES
MERCK &CO.
ELI LILLY
BRISTOL-MYERS SQUIBB
COMPETITORS IN JAPAN

NAME OF THE COUNTRY TOTAL REVENUE

(IN USD BILLIONS)

1. TAKEDAPHARMACEUTICAL. • 15.6

2. ASTELLAS PHARMA • 10.7

3. DAIICHI SANKYO
9 • 9

4. EISAI • 5.5

5. CHUGAI PHARMACEUTICAL • 2.0

.
TAKEDA PHARMACEUTICALS
ASTELLAS PHARMA
DAIICHI SANKYO
EISAI
CHUGAI PHARMACEUTICALS
COMPETITORS IN GERMANY

NAME OF THE COUNTRY TOTAL REVENUE

(IN USD BILLIONS)

1. BAYER • 22.3

2. BOEHRINGER • 16.9
INGELHEIM

3. MERCK kGaA • 5.17

BAYER
BOEHRINGER INGELHEIM
MERCK KGAA
COMPETITORS IN
SWITZERLAND

NAME OF THE COUNTRY TOTAL REVENUE

(IN USD BILLIONS)
1. HOFFMAN LA ROCHE • 47.35

2. NOVARTIS • 44.27

3. NYCOMED • 4.26
HOFFMAN LA ROCHE
NOVARTIS
NYCOMED
COMPETITORS IN UK

NAMEOF THE • TOTAL REVENUE

(IN USD BILLIONS)
COMPANY
1. GlaxoSmithKline • 45.83

2. AstraZeneca • 32.81
ASTRA ZENECA
SUBMITTED BY:
ISHDEEP SINGH
M100700019